Biologic therapy in asthma and COPD is changing the way these diseases are managed. There is a growing appreciation of the importance of the role that mucus plugs and the resulting ventilation defects play in disease progression and disease modification. By combining structural imaging (HRCT) with ventilation imaging (Xenon MRI), the functional consequences of these obstructions can be measured directly, and new insights gained in how to effectively phenotype patients for biologic therapy.

Join three leading pulmonology and imaging experts as they share important new data and case studies on how combining CT (structure) and Xenon MRI (function) offers a powerful biomarker combination to differentiate asthma phenotypes, monitor response to biologics, and even predict exacerbations.

We’ll dive into cutting-edge research and clinical applications, including: